Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

NCT ID: NCT01690091


Title
Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes
Purpose
The aim of the study is to evaluate the effect of metformin on myocardial function, insulin resistance and selected metabolic markers in patients with type 2 diabetes and heart failure (HF+DM+) in a cross-over, randomized, placebo controlled trial. Hypothesis: Metformin treatment in HF+DM+ group will lead to better myocardial function and load tolerance in comparison to placebo. The degree of improvement will be linked to selected metabolic parameters.
Details
40 patients with HF and DM without previous diabetes treatment will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET) - stratified randomization with following parameters weighted: HF etiology (ischemic /non-ischemic), diabetes duration, gender, BMI, age, NYHA, smoker/non-smoker). After 3 months the treatment will be switched. All participants will undergo standardized selection of metabolic and cardiovascular tests (hyperinsulinemic euglycemic clamp with indirect calorimetry, measurement of endothelial function, echocardiography, spiroergometry, proton/phosphor MR spectroscopy, adipose tissue biopsy, selected cytokines in plasma and adipose tissue at the beginning and the end of each intervention period (3 times in total).
Conditions
Insulin Resistance, Chronic Heart Failure
Keywords
chronic heart failure, type 2 diabetes, metformin, insulin resistance
Source
Institute for Clinical and Experimental Medicine
Sponsors
Institute for Clinical and Experimental Medicine
Status
Recruiting
Acronym
CARMET
Last Updated
02 Mar 2016
URL
Official Link
Locations
Czech Republic